The pathogenesis of Late-Life anemia

Blood Disorders in the Elderly

Volumn , Issue , 2007, Pages 203-213

  Kanapuru, Bindu ^a   Ershler, William B ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79960388975     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511545238.017     Document Type: Chapter

References (94)

1. Ershler WB. Biological interactions of aging and anemia: a focus on cytokines. J Am Geriatr Soc 2003; 51 (3 Suppl): S18-S21.
2. Gabrilove J. Anemia and the elderly: clinical considerations. Best Pract Res Clin Haematol 2005; 18: 417-22.
3. Artz AS, Fergusson D, Drinka PJ, et al. Mechanisms of unexplained anemia in the nursing home. J Am Geriatr Soc 2004; 52: 423-7.
4. Guralnik JM, Eisenstaedt RS, Ferrucci L, Klein HG, Woodman RC. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004; 104: 2263-8.
5. Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med 2000; 51: 245-70.
6. Blanc B, Finch CA, Hallberg L. Nutritional anaemias. Report of a WHO Scientific Group. WHO Tech Rep Ser 1968; 405: 1-40.
7. Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood 2006; 107: 1747-50.
8. Zakai NA, Katz R, Hirsch C, et al. A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: the Cardiovascular Health Study. Arch Intern Med 2005; 165: 2214-20.
9. Salive ME, Cornoni-Huntley J, Guralnik JM, et al. Anemia and hemoglobin levels in older persons: relationship with age, gender, and health status. J Am Geriatr Soc 1992; 40: 489-96.
10. Artz AS, Fergusson D, Drinka PJ, et al. Prevalence of anemia in skilled-nursing home residents. Arch Gerontol Geriatr 2004; 39: 201-6.
11. Ble A, Fink JC, Woodman RC, et al. Renal function, erythropoietin, and anemia of older persons: the In CHIANTI study. Arch Intern Med 2005; 165: 2222-7.
12. Narayanan S. Resource utilization and treatment trends of anemia in long term care residents. J Am Soc Nephrol 2005; 16: 549a.
13. Penninx BW, Guralnik JM, Onder G, Ferrucci L, Wallace RB, Pahor M. Anemia and decline in physical performance among older persons. Am J Med 2003; 115: 104-10.
14. Cesari M, Penninx BW, Lauretani F, et al. Hemoglobin levels and skeletal muscle: results from the In CHIANTI study. J Gerontol A Biol Sci Med Sci 2004; 59: 249-54.
15. Cesari M, Pahor M, Lauretani F, et al. Bone density and hemoglobin levels in older persons: results from the In CHIANTI study. Osteoporos Int 2005; 16: 691-9.
16. Penninx BW, Pahor M, Cesari M, et al. Anemia is associated with disability and decreased physical performance and muscle strength in the elderly. J Am Geriatr Soc 2004; 52: 719-24.
17. Penninx BW, Pluijm SM, Lips P, et al. Late-life anemia is associated with increased risk of recurrent falls. J Am Geriatr Soc 2005; 53: 2106-11.
18. Beard CM, Kokmen E, O’Brien PC, Ania BJ, Melton LJ, 3rd. Risk of Alzheimer’s disease among elderly patients with anemia: population-based investigations in Olmsted County, Minnesota. Ann Epidemiol 1997; 7: 219-24.
19. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-90.
20. Cumming RG, Mitchell P, Craig JC, Knight JF. Renal impairment and anaemia in a population-based study of older people. Intern Med J 2004; 34: 20-3.
21. Kosiborod M, Curtis JP, Wang Y, et al. Anemia and outcomes in patients with heart failure: a study from the National Heart Care Project. Arch Intern Med 2005; 165: 2237-44.
22. Nissenson AR, Goodnough LT, Dubois RW. Anemia: not just an innocent bystander? Arch Intern Med 2003; 163: 1400-4.
23. Culleton BF, Manns BJ, Zhang J, Tonelli M, Klarenbach S, Hemmelgarn BR. Impact of anemia on hospitalization and mortality in older adults. Blood 2006; 107: 3841-6.
24. Chaves PH, Xue QL, Guralnik JM, Ferrucci L, Volpato S, Fried LP. What constitutes normal hemoglobin concentration in community-dwelling disabled older women? J Am Geriatr Soc 2004; 52: 1811-16.
25. Rockey DC, Cello JP. Evaluation of the gastrointestinal tract in patients with iron-deficiency anemia. N Engl J Med 1993; 329: 1691-5.
26. Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin defi-ciency in the absence of anemia or macrocytosis. N Engl J Med 1988; 318: 1720-8.
27. Sears DA. Anemia of chronic disease. Med Clin North Am 1992; 76: 567-79.
28. Weiss G. Pathogenesis and treatment of anaemia of chronic disease. Blood Rev 2002; 16: 87-96.
29. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102: 783-8.
30. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004; 113: 1271-6.
31. Smith D. Management and treatment of anemia in the elderly. Clin Geriatr Med 2002; 10: 47-53.
32. Chatta GS, Lipschitz D. Anemia. In Hazzard WR, Blass JP, Ettinger WH, Halter JB, Ouslander JG, eds, Princi ples of Geriatric Medicine and Gerontology, 4th edn (New York, NY: McGraw-Hill, 1999), 899-906.
33. Chua E, Clague JE, Sharma AK, Horan MA, Lombard M. Serum transferrin receptor assay in iron deficiency anaemia and anaemia of chronic disease in the elderly. QJM 1999; 92: 587-94.
34. Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 2002; 100: 3776-81.
35. Baylis C, Schmidt R. The aging glomerulus. Semin Nephrol 1996; 16: 265-76.
36. Shumway JT, Gambert SR. Diabetic nephropathy: pathophysiology and management. Int Urol Nephrol 2002; 34: 257-64.
37. Clark B. Biology of renal aging in humans. Adv Ren Replace Ther 2000; 7: 11-21.
38. Spivak JL. Serum immunoreactive erythropoietin in health and disease. J Perinat Med 1995; 23: 13-7.
39. Kario K, Matsuo T, Kodama K, Nakao K, Asada R. Reduced erythropoietin secretion in senile anemia. Am J Hematol 1992; 41: 252-7.
40. Kario K, Matsuo T, Nakao K. Serum erythropoietin levels in the elderly. Gerontology 1991; 37: 345-8.
41. Powers JS, Krantz SB, Collins JC, et al. Erythropoietin response to anemia as a function of age. J Am Geriatr Soc 1991; 39: 30-2.
42. Bennett JM, Kouides PA, Forman SJ. The myelodysplastic syndromes: morphology, risk assessment, and clinical management (2002). Int J Hematol 2002; 76 (Suppl 2): 228-38.
43. Steensma DP, Bennett JM. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc 2006; 81: 104-30.
44. Shahidi NT. Androgens and erythropoiesis. N Engl J Med 1973; 289: 72-80.
45. Nissen C, Gratwohl A, Speck B. Management of aplastic anemia. Eur J Haematol 1991; 46: 193-7.
46. Schubert M, Jockenhovel F. Late-onset hypogonadism in the aging male (LOH): definition, diagnostic and clinical aspects. J Endocrinol Invest 2005; 28 (3 Suppl): 23-7.
47. Voegeli TA, Kurtz A, Grimm MO, Effert P, Eckardt KU. Anemia under androgen deprivation: influence of flutamide, cyproteroneacetate and orchiectomy on the erythropoietin system. Horm Metab Res 2005; 37: 89-93.
48. Visser M, Pahor M, Taaffe DR, et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol A Biol Sci Med Sci 2002; 57: M326-M332.
49. Cooper AC, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall IC. Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alpha, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. J Am Soc Nephrol 2003; 14: 1776-84.
50. Macdougall IC, Cooper AC. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 2002; 17 (Suppl 11): 39-43.
51. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998; 128: 127-37.
52. Cohen HJ, Pieper CF, Harris T, Rao KM, Currie MS. The association of plasma IL-6 levels with functional disability in community-dwelling elderly. J Gerontol A Biol Sci Med Sci 1997; 52: M201-M208.
53. Dentino AN, Pieper CF, Rao MK, et al. Association of interleukin-6 and other biologic variables with depression in older people living in the community. J Am Geriatr Soc 1999; 47: 6-11.
54. Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999; 106: 506-12.
55. Volpato S, Guralnik JM, Ferrucci L, et al. Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women’s health and aging study. Circulation 2001; 103: 947-53.
56. Ershler WB. Interleukin-6: a cytokine for gerontologists. J Am Geriatr Soc 1993; 41: 176-81.
57. Keller ET, Chang C, Ershler WB. Inhibition of NFkappaB activity through maintenance of IkappaBalpha levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter. J Biol Chem 1996; 271: 26267-75.
58. Keller ET, Wanagat J, Ershler WB. Molecular and cellular biology of interleukin-6 and its receptor. Front Biosci 1996; 1: d340-d357.
59. McKane WR, Khosla S, Peterson JM, Egan K, Riggs BL. Circulating levels of cytokines that modulate bone resorption: effects of age and menopause in women. J Bone Miner Res 1994; 9: 1313-18.
60. Kania DM, Binkley N, Checovich M, Havighurst T, Schilling M, Ershler WB. Elevated plasma levels of interleukin-6 in postmenopausal women do not correlate with bone density. J Am Geriatr Soc 1995; 43: 236-9.
61. Giuliani N, Sansoni P, Girasole G, et al. Serum interleukin-6, soluble interleukin-6 receptor and soluble gp130 exhibit different patterns of age-and menopause-related changes. Exp Gerontol 2001; 36: 547-57.
62. Roubenoff R, Harris TB, Abad LW, Wilson PW, Dallal GE, Dinarello CA. Monocyte cytokine production in an elderly population: effect of age and inflammation. J Gerontol A Biol Sci Med Sci 1998; 53: M20-M26.
63. Daynes RA, Araneo BA, Ershler WB, Maloney C, Li GZ, Ryu SY. Altered regulation of IL-6 production with normal aging. Possible linkage to the age-associated decline in dehydroepiandrosterone and its sulfated derivative. J Immunol 1993; 150: 5219-30.
64. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 1997; 8: 963-8.
65. Ferrucci L, Harris TB, Guralnik JM, et al. Serum IL-6 level and the development of disability in older persons. J Am Geriatr Soc 1999; 47: 639-46.
66. Leng S, Chaves P, Koenig K, Walston J. Serum interleukin-6 and hemoglobin as physiological correlates in the geriatric syndrome of frailty: a pilot study. J Am Geriatr Soc 2002; 50: 1268-71.
67. Baraldi-Junkins CA, Beck AC, Rothstein G. Hematopoiesis and cytokines. Relevance to cancer and aging. Hematol Oncol Clin North Am 2000; 14: 45-61, viii.
68. Dai C, Krantz SB. Interferon gamma induces upregulation and activation of caspases 1, 3, and 8 to produce apoptosis in human erythroid progenitor cells. Blood 1999; 93: 3309-16.
69. Ferrucci L, Guralnik JM, Woodman RC, et al. Proinflammatory state and circulating erythropoietin in persons with and without anemia. Am J Med 2005; 118: 1288.
70. Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 1998; 18: 555-9.
71. Jelkmann W, Pagel H, Wolff M, Fandrey J. Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. Life Sci 1992; 50: 301-8.
72. Ershler WB, Sheng S, McKelvey J, et al. Serum erythropoietin and aging: a longitudinal analysis. J Am Geriatr Soc 2005; 53: 1360-5.
73. Bertero MT, Caligaris-Cappio F. Anemia of chronic disorders in systemic autoimmune diseases. Haematologica 1997; 82: 375-81.
74. Goodnough LT, Price TH, Parvin CA. The endogenous erythropoietin response and the erythropoietic response to blood loss anemia: the effects of age and gender. J Lab Clin Med 1995; 126: 57-64.
75. Andrews NC. Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest 2004; 113: 1251-3.
76. Lee P, Peng H, Gelbart T, Wang L, Beutler E. Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci USA 2005; 102: 1906-10.
77. Ganz T, Nemeth E. Iron imports. IV. Hepcidin and regulation of body iron metabolism. Am J Physiol Gastrointest Liver Physiol 2006; 290: G199-G203.
78. Roy CN, Andrews NC. Anemia of inflammation: the hepcidin link. Curr Opin Hematol 2005; 12: 107-11.
79. Roy CN, Enns CA. Iron homeostasis: new tales from the crypt. Blood 2000; 96: 4020-7.
80. Deicher R, Horl WH. Hepcidin: a molecular link between inflammation and anaemia. Nephrol Dial Transplant 2004; 19: 521-4.
81. Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002; 110: 1037-44.
82. Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005; 106: 1864-6.
83. Sharma N, Laftah AH, Brookes MJ, Cooper B, Iqbal T, Tselepis C. A role for tumour necrosis factor alpha in human small bowel iron transport. Biochem J 2005; 390: 437-46.
84. Williams LH, Udupa KB, Lipshitz DA. Evaluation of the effect of age on hematopoiesis in the C57BL/6 mouse. Exp Hematol 1986; 14: 827-32.
85. Boyer SH, Bishop TR, Rogers OC, Noyes AN, Frelin LP, Hobbs S. Roles of erythropoietin, insulin-like growth factor 1, and unidentified serum factors in promoting maturation of purified murine erythroid colonyforming units. Blood 1992; 80: 2503-12.
86. Koury MJ, Bondurant MC. Maintenance by erythropoietin of viability and maturation of murine erythroid precursor cells. J Cell Physiol 1988; 137: 65-74.
87. Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 1990; 248: 378-81.
88. Felli N, Pedini F, Zeuner A, et al. Multiple members of the TNF superfamily contribute to IFN-gammamediated inhibition of erythropoiesis. J Immunol 2005; 175: 1464-72.
89. Zamai L, Secchiero P, Pierpaoli S, et al. TNF-related apoptosis-inducing ligand (TRAIL) as a negative regulator of normal human erythropoiesis. Blood 2000; 95: 3716-24.
90. Campioni D, Secchiero P, Corallini F, et al. Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am J Pathol 2005; 166: 557-63.
91. Moldawer LL, Marano MA, Wei H, et al. Cachectin/tumor necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo. Faseb J 1989; 3: 1637-43.
92. Rothstein G. Disordered hematopoiesis and myelodysplasia in the elderly. J Am Geriatr Soc 2003; 51 (3 Suppl): S22-S26.
93. Ershler WB, Sun WH, Binkley N, et al. Interleukin-6 and aging: blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction. Lymphokine Cytokine Res 1993; 12: 225-30.
94. Ershler WB. Inflammation gone awry: aging or disease. Blood 2005; 105: 2247.